|
US20130202639A1
(en)
*
|
2010-03-25 |
2013-08-08 |
Konstantin G. Kousoulas |
Synthetic Herpes Simplex Viruses for Treatment of Cancers
|
|
GB201006405D0
(en)
|
2010-04-16 |
2010-06-02 |
Isis Innovation |
Poxvirus expression system
|
|
KR20170039774A
(en)
*
|
2012-07-30 |
2017-04-11 |
알렉스 와 힌 영 |
Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator
|
|
EP3324988B1
(en)
|
2015-07-20 |
2021-03-03 |
Virttu Biologics Limited |
Use of oncolytic herpes simplex virus in combination with immune checkpoint inhibitor, in the treatment of cancer
|
|
ES3041885T3
(en)
|
2016-01-08 |
2025-11-17 |
Replimune Ltd |
Engineered virus
|
|
EP3426271B1
(en)
|
2016-03-10 |
2025-08-27 |
CG Oncology, Inc. |
Methods of treating solid tumors by combination therapy
|
|
KR102536850B1
(en)
|
2016-04-15 |
2023-05-26 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
ICOS Ligand Variant Immunomodulatory Proteins and Uses Thereof
|
|
IL262366B2
(en)
|
2016-04-15 |
2024-07-01 |
Alpine Immune Sciences Inc |
Immunomodulatory proteins and CD80 variants and their uses
|
|
EP3491013A1
(en)
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
EP3529361B1
(en)
|
2016-10-20 |
2021-03-24 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
EP3580341A4
(en)
|
2017-02-09 |
2020-11-04 |
Indapta Therapeutics, Inc. |
MANIPULATED NATURAL KILLER (NK) CELLS AND COMPOSITIONS AND METHOD FOR THEREFORE
|
|
CN119161451A
(en)
|
2017-03-16 |
2024-12-20 |
高山免疫科学股份有限公司 |
PD-L1 variant immunomodulatory protein and its use
|
|
JP2020511144A
(en)
|
2017-03-16 |
2020-04-16 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
PD-L2 variant immunomodulatory proteins and uses thereof
|
|
CA3054068A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
AU2018251987B2
(en)
|
2017-04-14 |
2024-11-28 |
Cg Oncology, Inc. |
Methods of treating bladder cancer
|
|
KR102813968B1
(en)
|
2017-10-10 |
2025-05-29 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
|
AU2018351000B2
(en)
|
2017-10-18 |
2023-11-30 |
Alpine Immune Sciences, Inc. |
Variant ICOS Ligand immunomodulatory proteins and related compositions and methods
|
|
CA3087149A1
(en)
|
2018-01-03 |
2019-07-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
US12065476B2
(en)
|
2018-06-15 |
2024-08-20 |
Alpine Immune Sciences, Inc. |
PD-1 variant immunomodulatory proteins and uses thereof
|
|
CN113891934A
(en)
|
2018-11-21 |
2022-01-04 |
因达普塔治疗公司 |
Methods of expanding Natural Killer (NK) cell subsets and related compositions and methods
|
|
TW202038947A
(en)
|
2018-11-28 |
2020-11-01 |
德商創新分子有限責任公司 |
Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses
|
|
CA3120868A1
(en)
|
2018-11-30 |
2020-06-04 |
Alpine Immune Sciences, Inc. |
Cd86 variant immunomodulatory proteins and uses thereof
|
|
JP2023523429A
(en)
|
2020-04-22 |
2023-06-05 |
インダプタ セラピューティクス インコーポレイテッド |
Natural killer (NK) cell compositions and methods for producing same
|
|
CN111850126B
(en)
*
|
2020-08-06 |
2022-11-01 |
北京市神经外科研究所 |
Application of oncolytic virus in treatment of uveal melanoma, marker of treatment effect and detection reagent thereof
|